Evaluation of myocardial revascularization utilizing Tc-99m pyrophosphate.

Early clinical application of technetium 99m labeled pyrophosphate for cardiac imaging has revealed a safe noninvasive method of determining areas of impaired myocardial perfusion in patients with atherosclerotic occlusive coronary artery disease. Using this method, we were able to demonstrate improvement in myocardial blood supply following coronary artery bypass surgery.